Xerava generic
Xerava is an antibacterial drug owned by Tetraphase Pharms. It contains the active ingredient eravacycline dihydrochloride. The drug was first authorized for market use on 27 August, 2018 and is available in powder;intravenous dosage forms.
When will Xerava generic be available?
Xerava's last patent is set to expire on 19 October, 2037. Post this date, generic versions of Xerava may be available. Meanwhile, drug patent challenges can be filed against Xerava from 28 August, 2027 onwards.
Xerava uses
Xerava is used for the treatment of complicated intra-abdominal infections in patients aged 18 years and older. Its active ingredient, eravacycline dihydrochloride, targets and kills bacteria causing the infection.
Xerava patent expiration
Xerava has a total of 4 drug patents, none of which have expired. The most recent patent ('Crystalline forms of eravacycline') is expected to expire on 19 October, 2037. Below are the details of the patent: